Mullins R J
Department of Surgery, Oregon Health Science University, Portland 97201-3098.
J Trauma. 1991 Jul;31(7):934-40; discussion 940-1. doi: 10.1097/00005373-199107000-00009.
The purpose of this experiment was to determine in skin microvasculature the dose response to bradykinin (BRADY). Over a range 0, 0.2, 0.4, and 0.8 microgram/kg/min BRADY was infused into the femoral artery of anesthetized dogs while lymph was collected from the hind paw. After 4 hours of continuous BRADY, venous pressure was increased 20 to 30 mm Hg by tightening a tourniquet around the thigh to further increase lymph flow and achieve a filtration-independent lymph-plasma ratio, for albumin (R Alb), immunoglobulin G (R IgG), and immunoglobulin M (R IgM). These proteins were measured with immunoelectrophoresis and immunodiffusion. MEAN +/- SD, * p less than 0.05, ANOVA, DIFFERENT FROM LOWER DOSE. [Formula: see text] BRADY caused a dose-related increase in microvascular permeability up to 0.4 microgram/kg/min. The increase in the lymph-plasma ratio for the large plasma proteins (IgM, molecular radius 110 A) is of the same magnitude as for albumin, (molecular radius 36 A), and this suggests BRADY increased the number but not the size of "large pores" in the microvascular membrane.
本实验的目的是确定皮肤微血管对缓激肽(BRADY)的剂量反应。在0、0.2、0.4和0.8微克/千克/分钟的范围内,将缓激肽注入麻醉犬的股动脉,同时从后爪收集淋巴液。持续输注缓激肽4小时后,通过在大腿周围收紧止血带来增加静脉压力20至30毫米汞柱,以进一步增加淋巴液流量,并实现与滤过无关的白蛋白(R Alb)、免疫球蛋白G(R IgG)和免疫球蛋白M(R IgM)的淋巴-血浆比率。这些蛋白质通过免疫电泳和免疫扩散进行测量。均值±标准差,*p<0.05,方差分析,与较低剂量不同。[公式:见正文]缓激肽在高达0.4微克/千克/分钟的剂量范围内导致微血管通透性呈剂量相关增加。大分子血浆蛋白(IgM,分子半径110 Å)的淋巴-血浆比率增加幅度与白蛋白(分子半径36 Å)相同,这表明缓激肽增加了微血管膜中“大孔”的数量而非大小。